Lenacapavir-injection

Lenacapavir: The Future of HIV Treatment & PrEP — But What About India?

Medically reviewed by

If you follow global HIV breakthroughs, you’ve surely heard about Lenacapavir — a revolutionary twice-a-year injection that’s changing how we think about HIV prevention (PrEP) and treatment (ART).

Approved under the brand names Sunlenca® (for treatment) and Yeztugo® (for PrEP), Lenacapavir is hailed for its convenience: just one injection every six months instead of daily pills.

How does Lenacapavir help?

  • For people with drug-resistant HIV, Sunlenca® offers fresh hope.
  • For HIV-negative people at risk, Yeztugo® promises long-lasting protection.

Side effects? Mostly mild: injection site pain, headache, nausea.

The catch? It’s not available in India yet — and costs a whopping $28,000–$30,000 USD per year (₹23–25 lakh). Realistically, it may take 1.5–2 years (or more) to arrive and become affordable here.

What’s your best option until then?

👉 Daily oral PrEP is proven, safe, and costs only ₹1,000–₹2,500 per month.

At DrSafeHands, we make PrEP easy: discreet counseling, expert doctors, and home delivery.

💡 Why wait? Protect yourself today, not years later.


Who Can Use Lenacapavir?

Lenacapavir is approved for use in adults with HIV-1 infection who are heavily treatment-experienced and whose virus is resistant to multiple classes of HIV medications. Your HIV specialist at DrSafeHands will assess your eligibility based on your medical history and viral resistance profile.


Call Now Button